Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/01.cir.62.2.212 | DOI Listing |
Swiss Med Wkly
January 2025
Department of Internal Medicine, Clinic for Medical Oncology and Hematology, Municipal Hospital Zurich Triemli, Zurich, Switzerland.
Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens with or without autologous or allogenic transplantation were the cornerstone of most therapeutic concepts.
View Article and Find Full Text PDFDrug Alcohol Depend Rep
March 2025
Community Health and Implementation Research Program, RTI International, Research Triangle Park, NC, USA.
Background: In response to the recent and growing shift from injecting heroin to smoking fentanyl, an increasing number of syringe services programs (SSPs) in the United States are distributing safer smoking supplies. There is a lack of research on whether safer smoking supply distribution is associated with increased SSP engagement and naloxone distribution from SSPs. Therefore, we aimed to assess predictors of safer smoking supply distribution by SSPs and estimate associations between safer smoking supply distribution and scale of harm reduction services.
View Article and Find Full Text PDFJACC Adv
February 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Background: Assessing individuals' risk of developing incident atrial fibrillation (AF) is important for making preventive and screening strategies.
Objectives: The performance of the mCHEST score for predicting incident AF has scarcely been evaluated, especially in a multi-ethnic population.
Methods: Participants from the MESA (Multi-Ethnic Study of Atherosclerosis were enrolled in the present study, which involved population of different ethnicities (Caucasian, African-American, Chinese-American, and Hispanic) aged between 45 and 84 from 6 communities in the United States.
Unlabelled: Transparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity.
View Article and Find Full Text PDFUnlabelled: Early phase dose-finding (EPDF) trials are key in the development of novel therapies, with their findings directly informing subsequent clinical development phases and providing valuable insights for reverse translation. Comprehensive and transparent reporting of these studies is critical for their accurate and critical interpretation, which may improve and expedite therapeutic development. However, quality of reporting of design characteristics and results from EPDF trials is often variable and incomplete.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!